Melanoma: Complete response to anti-PD-1s 'generally durable'
But the results of retreating relapsed patients are disappointing, say researchers
17th February 2020
By Clare Pain
Three years after starting anti-PD-1 therapy, most patients who have complete response maintain that status despite stopping their treatment.